Genmab A/S announced positive topline results from Phase 3 RAINFOL-02, in which investigational Rina-S met the primary endpoint of progression-free survival (PFS) and key secondary endpoint of overall survival (OS) versus investigator’s choice chemotherapy in platinum-resistant ovarian cancer. For PFS, hazard ratios were 0.29 in the intent-to-treat (ITT) population of 584 patients and 0.33 in the primary analysis set (PAS) of 492 patients; Genmab reported 71% and 67% reductions in risk of progression or death, respectively. For OS, hazard ratios were 0.43 in ITT and 0.44 in PAS. All four comparisons had p<0.0001.
Genmab said the observed safety profile was consistent with Rina-S’s known profile, with no new safety signals or unexpected safety concerns identified. The company plans to discuss potential next steps with regulatory authorities worldwide and submit the data for presentation at a future medical meeting. Rina-S remains investigational; its safety and efficacy have not been established.
Genmab A/S reported worldwide net trade sales of DARZALEX (daratumumab), including the subcutaneous product, of USD 4,239 million in the third quarter of 2026, as reported by Johnson & Johnson (J&J). The total comprised USD 2,528 million in the U.S. and USD 1,711 million in the rest of the world.
Genmab receives royalties on worldwide net sales of both the intravenous and subcutaneous products under its exclusive worldwide license to J&J to develop, manufacture and commercialize daratumumab.
Genmab A/S shareholders at an Extraordinary General Meeting approved the Board of Directors’ 2026 remuneration proposal, including restricted stock units (RSUs). The approval resulted in 5,300 RSUs being granted to Board members under the company’s Remuneration Policy. Each RSU was awarded cost-free and gives its owner a conditional right to receive one Genmab A/S share with a nominal value of DKK 1. The fair value per RSU was DKK 2,487.00, equal to the share’s closing market price on the grant date. The RSUs vest on the first banking day of the month following a period of three years from the grant date and are subject to the Remuneration Policy and applicable RSU program.
For Genmab A/S ordinary shares, Darwin Global Management, Ltd. and Dr. Abhishek Trehan each report beneficial ownership of 3,668,310 shares (5.9%), with shared voting and dispositive power. Dr. Trehan is identified as Darwin Global’s chief investment officer and controlling person.
The reported amount consists of 1,825,006 ordinary shares and 18,433,047 ADSs representing 1,843,304 ordinary shares. Darwin Global Master Fund Ltd. reports beneficial ownership of 3,569,746 shares (5.7%), consisting of 1,775,809 ordinary shares and 17,939,370 ADSs representing 1,793,937 ordinary shares. The percentages use 62,405,855 ordinary shares reported outstanding in an exhibit to a Form 6-K filed September 9, 2026. The reporting persons state that their disclosure is not an admission that any of them is a beneficial owner for purposes of the Securities Exchange Act of 1934.
Genmab A/S and AbbVie reported positive topline results from the Phase 3 EPCORE DLBCL-2 trial of epcoritamab plus R-CHOP in newly diagnosed diffuse large B-cell lymphoma (DLBCL). Among patients with International Prognostic Index (IPI) scores of 2–5, the combination reduced the risk of disease progression or death by 51% versus R-CHOP alone (HR 0.49; 95% CI 0.36–0.67; p-value < 0.0001). In the primary-endpoint group with IPI scores of 3–5, risk was also reduced by 51% (HR 0.49; 95% CI 0.35–0.69; p-value < 0.0001). The combination's safety profile was generally well tolerated and consistent with the previously reported profiles of epcoritamab and R-CHOP. Epcoritamab plus R-CHOP remains investigational and is not approved by regulatory authorities; Genmab and AbbVie will engage global regulatory authorities to determine next steps. The trial is ongoing.
Genmab A/S announced that Darwin Global Management Limited informed it that, as of September 28, 2026, Darwin controlled voting rights attached to 3,188,361 shares in Genmab, corresponding to 5.11% of voting rights. Darwin’s position was through shares and ADRs held by certain investment funds and portfolios for which Darwin acts as investment manager.
Genmab A/S granted 13,794 restricted stock units and 13,331 warrants to employees of the company and its subsidiaries. Each cost-free RSU gives a conditional right to one share; its fair value was DKK 2,268, equal to the grant-date closing share price. RSUs vest on the first banking day of the month following three years from grant, subject to program conditions. Each cost-free warrant permits subscription for one share at an exercise price of DKK 2,268; warrants vest after three years and expire at the seventh anniversary of grant. Their Black-Scholes fair value was DKK 781.96.
Genmab A/S (GMAB) filed a Form 6-K as a foreign private issuer for September 2026, primarily to furnish an updated Articles of Association as Exhibit 3.1. The filing states that this report is incorporated by reference into Genmab’s existing Form S-8 registration statements.
Genmab A/S (GMAB) is convening an Extraordinary General Meeting on October 7, 2026 to seek shareholder approval of the Board of Directors’ remuneration for 2026 after the prior proposal was withdrawn at the March 19, 2026 annual meeting. The Board proposes that director compensation, including cash fees and share-based pay, remains unchanged from 2024 and 2025 under the existing Remuneration Policy.
Base fees include DKK 600,000 for board members, with the chair receiving 2x and the deputy chair 1.5x that amount, plus specified committee fees and DKK 10,000 per committee meeting. Directors receive restricted stock units, with the chair granted RSUs equal to 3x the base fee and other directors 2.5x. The company reports share capital of DKK 62,377,844, with one vote per DKK 1 share, and outlines detailed registration, proxy and postal voting procedures ahead of the simple-majority vote on the proposal.